| Name | Title | Contact Details |
|---|---|---|
Joshua Grass |
Chief Executive Officer | Profile |
Nortern Lipids is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Lion Biotechnologies (LBIO) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). Under a collaborative research and development agreement with Dr. Steven A. Rosenberg at the National Cancer Institute, we are investigating our our lead product candidate, LN-144, in the treatment of stage 4 metastatic melanoma. In clinical trials, LN-144 has demonstrated curative potential in patients with metastatic melanoma, and it may also be applicable to a wide range of other solid tumors. As we continue advancing our current clinical programs in collaboration with NCI, Moffitt Cancer Center and MD Anderson, we are also developing next-generation TIL products and an optimized manufacturing process that will enable the production of highly potent, engineered cells at a significantly reduced cost. With unique and versatile technology, promising clinical programs, strong intellectual property, high-profile collaborations and seasoned leadership, Lion is committed to elevating hope and treatment standards for patients, while creating exceptional value for its shareholders.
SelectX Pharmaceuticals, Inc. is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
We are a clinical stage development and licensing biotechnology company focused on leveraging our Pfenex Expression Technology™ platform to develop and improve protein therapies for unmet patient needs.
SalioGen Therapeutics is advancing the Exact DNA Integration Technology (EDIT) platform, the only genome engineering technology that is mammal-derived, for use in potentially curative non-viral gene therapy.